Status:
UNKNOWN
Ivermectin In Treatment of COVID 19 Patients
Lead Sponsor:
Ministry of Health and Population, Egypt
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of n...
Detailed Description
the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients
Eligibility Criteria
Inclusion
- Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap
Exclusion
- Contraindications for the drug: hypersensitivity.
- Any medications with possible drug interactions.
- Severe cases.
- Any malignant condition.
- Pregnant females.
- Breast feeding females.
- Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.
Key Trial Info
Start Date :
June 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04425707
Start Date
June 9 2020
End Date
September 1 2020
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
isolation and referal hospitals for COVID 19 patients
Cairo, Egypt